Table 4.
Association between clinicopathological factors and hypermethylation of at least one gene for breast cancer, WEB Study, 1996–2001a
| All subjects
|
Premenopausal
|
Postmenopausal
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | ORb (95% CI) | Yes | No | ORb (95% CI) | Yes | No | ORb (95% CI) | |
| Tumor size (cm) | |||||||||
| < 1.0 | 115 | 50 | 1.0 | 22 | 11 | 1.0 | 93 | 39 | 1.0 |
| 1.0–1.4 | 110 | 58 | 0.87 (0.57–1.33) | 28 | 17 | 0.63 (0.27–1.47) | 82 | 41 | 0.97 (0.60–1.58) |
| 1.5–2.1 | 134 | 64 | 0.98 (0.65–1.47) | 38 | 19 | 0.75 (0.33–1.70) | 96 | 45 | 1.06 (0.66–1.69) |
| ≥2.2 | 127 | 68 | 0.87 (0.58–1.31) | 53 | 26 | 0.76 (0.36–1.63) | 74 | 42 | 0.88 (0.54–1.45) |
| Metastatic disease at presentation | |||||||||
| No | 367 | 186 | 1.0 | 93 | 55 | 1.0 | 274 | 131 | 1.0 |
| Yes | 139 | 68 | 1.05 (0.74–1.48) | 61 | 20 | 1.89 (1.02–3.50) | 78 | 48 | 0.78 (0.51–1.19) |
| Vascular/lymph invasion | |||||||||
| No | 349 | 185 | 1.0 | 92 | 55 | 1.0 | 257 | 130 | 1.0 |
| Yes | 146 | 67 | 1.16 (0.82–1.63) | 62 | 20 | 1.89 (1.03–3.47) | 84 | 47 | 0.90 (0.60–1.37) |
| Histological grade | |||||||||
| Well | 57 | 25 | 1.0 | 11 | 8 | 1.0 | 46 | 17 | 1.0 |
| Moderate | 157 | 83 | 0.94 (0.64–1.36) | 47 | 19 | 1.11 (0.52–2.39) | 110 | 64 | 0.87 (0.57–1.35) |
| Poor | 212 | 101 | 1.05 (0.73–1.51) | 71 | 39 | 0.84 (0.42–1.65) | 141 | 62 | 1.17 (0.76–1.80) |
| Nuclear grade | |||||||||
| I | 99 | 46 | 1.0 | 21 | 9 | 1.0 | 78 | 37 | 1.0 |
| II | 173 | 92 | 0.84 (0.57–1.23) | 51 | 24 | 0.85 (0.39–1.89) | 122 | 68 | 0.82 (0.53–1.27) |
| III | 205 | 104 | 0.88 (0.61–1.29) | 75 | 39 | 0.77 (0.37–1.62) | 130 | 65 | 0.93 (0.60–1.45) |
| TNM stage | |||||||||
| 0 | 57 | 34 | 1.0 | 22 | 7 | 1.0 | 35 | 27 | 1.0 |
| I | 223 | 112 | 0.94 (0.64–1.39) | 49 | 31 | 0.51 (0.22–1.15) | 174 | 81 | 1.15 (0.74–1.79) |
| IIa/IIb | 160 | 82 | 0.95 (0.63–1.44) | 57 | 31 | 0.59 (0.26–1.33) | 103 | 51 | 1.13 (0.69–1.85) |
| III/IV | 33 | 14 | 1.13 (0.56–2.30) | 19 | 4 | 1.55 (0.43–5.59) | 14 | 10 | 0.77 (0.31–1.86) |
| ER status | |||||||||
| + | 352 | 179 | 1.0 | 95 | 45 | 1.0 | 257 | 134 | 1.0 |
| − | 158 | 75 | 1.11 (0.80–1.56) | 52 | 28 | 0.95 (0.52–1.73) | 106 | 47 | 1.22 (0.81–1.83) |
| PR status | |||||||||
| + | 307 | 166 | 1.0 | 98 | 50 | 1.0 | 209 | 116 | 1.0 |
| − | 189 | 80 | 1.31 (0.95–1.82) | 46 | 21 | 1.20 (0.63–2.28) | 143 | 59 | 1.39 (0.95–2.04) |
| ER/PR | |||||||||
| Both − | 270 | 147 | 1.0 | 80 | 41 | 1.0 | 190 | 106 | 1.0 |
| Either + | 106 | 43 | 1.35 (0.90–2.01) | 31 | 11 | 1.42 (0.65–3.10) | 75 | 32 | 1.34 (0.84–2.16) |
| Both + | 116 | 54 | 1.18 (0.81–1.72) | 32 | 18 | 0.91 (0.46–1.83) | 84 | 36 | 1.34 (0.85–2.11) |
| p53 mutation | |||||||||
| Wild | 165 | 326 | 1.0 | 53 | 96 | 1.0 | 112 | 230 | 1.0 |
| Mutant | 61 | 132 | 1.10 (0.77–1.57) | 18 | 46 | 1.42 (0.74–2.71) | 43 | 86 | 0.97 (0.63–1.49) |
a
Numbers for some analyses are less than total for entire group because of missing variables
b
Odds ratios (ORs) and 95% confidence intervals (CI) were estimated with unconditional logistic model adjusted for age at diagnosis for breast cancer, race, and education